Skip to Main Content

John Buolamwini, PhD

Chair of Pharmaceutical Sciences, Professor

Dr. Buolamwini has held faculty positions in the United States for the past 26years, including the University of Mississippi and the University of Tennessee, where he served as the Vice Chair and Director of Graduate Programs of the Department of Pharmaceutical Sciences from 2012-2014. Dr. Buolamwini has also trained seven PhD scholars and ten postdoctoral associates.

Dr. Buolamwini’s research is in the area of drug design and discovery, and experimental therapeutics in several disease areas, primarily heart disease, cancer and HIV/AIDS. He is also an inventor on several patents on novel bioactive molecules. His research has been continuously funded for over 20years by organizations such as the American Heart Association, the National Heart Lung and Blood Institute, the National Cancer Institute, the National Institute of Allergy and Infectious Diseases and the National Institute on Aging.

CURRICULUM VITAE

Recent Publications

  1. Wang, C., Buolamwini*, J.K.(2019) A novel RNA variant of human concentrative nucleoside transporter 1 (hCNT1) that is a potential cancer biomarker. Exp Hematol Oncol., 8 18.PMCID:PMC6704654
  2. Deokar, H., Deokar, M., Wang, W., Zhang, R., Buolamwini*, J.K. (2018) QSAR Studies of New Pyrido[3,4-b]indole Derivatives as Inhibitors of Colon and Pancreatic Cancer Cell Proliferation. Med. Chem. Res. 27, 2466-2481.
  3. Qin, J.-J., Wang, W. Li, X., Deokar, H., Buolamwini, J. K., Zhang, R.(2018) Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy.Frontiers Pharmacol.9, 5. doi:
  4. Deokar, H., Barch, H. P., Buolamwini*, JK (2017) Homology Modeling of Human Concentrative Nucleoside Transporters (hCNTs) and Validation by Virtual Screening and Experimental Testing to Identify Novel hCNT1 Inhibitors. Drug Des6: 146. doi: 10.4172/2169-0138.1000146
  5. Patil, S.A., Addo, J.K., Deokar, H., Sun. S., Wang. J., Li, W., Suttle, D.P., Wang, W., Zhang* R, Buolamwini* JK(2017) Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-b]indole Derivatives as Broad-Spectrum Potent Anticancer Agents.Drug Des6: 143. doi: 10.4172/2169-0138.1000143
  6. Sun, S., Yue, P., He, M., Zhang, X., Paladino, D., Al-Abed, Y., Turkson*, J., Buolamwini* J.K. (2017) An Integrated Computational and Experimental Binding Study Identifies the DNA Binding Domain as the Putative Binding Site of Novel Pyrimidinetrione Signal Transducer and Activator of Transcription 3 (STAT3) Inhibitors. Drug Des6: 142. doi: 10.4172/2169-0138.1000142
  7. Nag, S., Qin, J.J., Voruganti, S., Wang, M.H., Sharma, H., Patil, S.,Buolamwini,J.K., Wang, W., Zhang* R. (2015) Biomed. Chromatogr. 29, 654-63.
  8. 8.Playa. H., Lewis, T.A., Ting, A., Suh, B.C., Muñoz, B., Matuza, R., Passer, B.J., Schreiber, S,L.,Buolamwini*,J.K. (2014). Dilazep analogues for the study of equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2). Bioorg. Med. Chem. Lett.24, 5801-4.29,654-6371.
  9. Wang, W., Qin, J.J., Voruganti, S., Srivenugopal, K.S., Nag, S., Patil, S., Sharma, H., Wang, M.H., Wang, H, Buolamwini*JK, Zhang* R. (2014) A Novel Pyrido[b]indole MDM2 Inhibitor, SP-141, Exerts Potent Therapeutic Effects in Breast Cancer Models. Nature Commun. 5, 5086. doi: 10.1038/ncomms6086.
  10. Nag, S., Qin, J.J., Patil, S., Deokar, H.,Buolamwini,J.K., Wang, W., Zhang, R. (2014) A quantitative LC-MS/MS method for determination of SP-141, a novel pyrido[b]indole anticancer agent, and its application to a mouse PK Study.J. Chromatogr B Analyt Technol Biomed Life Sci.969C:235-240.
  11. Wang, W., J.-J., Voruganti, S.,Wang, M.-H., Sharma, H., Patil, S., Zhou, J., Wang, H., Mukhopadhyay,D. Buolamwini*, J.K.and Zhang*, R. (2014) Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice. Gastroenterology 147, 893-902.e2.
  12. Chen Q,Buolamwini JK, Smith JC, Li A, Xu Q, Cheng X, Wei D. (2013) Impact of Resistance Mutations on Inhibitor Binding to HIV-1 Integrase.J Chem Inf Model. 53, 3297-307
  13. Wang, C., Playa, H., Sun, S., Cameron, K., and Buolamwini,* J.K. (2013) Dipyridamole analogues as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4). Biochem. Pharmacol.86, 1531-40.
  14. Sharma, H., Sanchez, T., Detorio, M., Schinazi, R. S., Neamati, N. and Buolamwini*, J. K.(2013) Synthesis, docking, and biological studies of phenanthrene beta-diketo acids as novel HIV-1 integrase inhibitors Bioorg. Med. Chem. Lett23, 6146-51
  15. Lu, C., Liu, D., Jin, J., Deokar, H., Zhang, Y., Buolamwini, J. K., Yu, X., Yan, C., Chen, X. (2013) Inhibition of gastric tumor growth by a novel HSP90 inhibitor. Biochem. Pharmacol.85, 1246-1256
  16. Wang, C., Schwab, L. P., Seagroves,T. N., Fan, M. and Buolamwini*,J. K. (2013)Chemoprevention Activity of Dipyridamole in the MMTV-PyMT Transgenic Mouse Model of Breast Cancer. Cancer Prev. Res. 6, 437-447.
  17. Yang, X., Wang, W., Qin, J., Wang, M.-H., Sharma, H., Buolamwini, J.K., Wang, H., Zhang, R. (2012) JKA97, a Novel Benzylidene Analog of Harmine, Exerts Anti-Breast Cancer Effects by Inducing G1 Arrest, Apoptosis, and p53-Independent Up-regulation of p21.PloSOne 7(4):e34303.
  18. Sharma, H., Cheng, X., Buolamwini*, J. K.(2012) Homology Model-Guided 3D-QSAR Studies of HIV-1 Integrase Inhibitors. J. Chem. Info. Model. 52, 515-544.
  19. Sharma, H., Patil, S., Sanchez, T. W., Neamati, N., Schinazi, R. F., Buolamwini*, J. K. (2011) Synthesis, Biological Evaluation and 3D-QSAR Studies of 3-Keto Salicylic Acid Chalcones and Related Amides as Novel HIV-1 Integrase Inhibitors. Bioorg. Med. Chem. 19, 2030-2045.
    This paper was among Science Direct’s Top 25 most downloaded articles published in 2011; and also featured in the top-10 percentile of cited chemistry articles published in 2011.
  20. Lin, W., Buolamwini*, J. K. (2011) Design, synthesis and evaluation of 2-diethanolamino-4,8-diheptamethyleneimino-2-(N-aminoethyl-N-ethanolamino)-6-(N,N-diethanolamino)pyrimido[5,4-d]pyrimidine-fluorescein conjugate (8MDP-fluor), as a novel equilibrative nucleoside transporter probe. Bioconjugate Chemistry22, 1221-1227.

*Corresponding/senior author